Zheng Quan Ri Bao Wang·2026-02-26 13:12Group 1 - The core viewpoint of the news is that BeiGene Limited reported a significant increase in revenue and net profit for the fiscal year 2025, driven by product sales growth and improved operational efficiency [1][2] Group 2 - For the fiscal year 2025, the total revenue reached 38.205 billion yuan, representing a year-on-year growth of 40.4% [1] - The net profit attributable to the parent company was 1.422 billion yuan, reflecting strong financial performance [1] - Product revenue amounted to 37.770 billion yuan, with a year-on-year increase of 39.9%, primarily due to the sales growth of the drug Brukinsa (Zebutinib) and other licensed products [1] Group 3 - Brukinsa achieved record global sales of 28.067 billion yuan, with a year-on-year growth of 48.8% [1] - In the U.S. market, Brukinsa's annual sales reached 20.206 billion yuan, growing by 45.5% [1] - In Europe, Brukinsa's annual sales were 4.265 billion yuan, with a significant increase of 66.4% [1] - In China, Brukinsa's annual sales reached 2.472 billion yuan, marking a growth of 33.1% [1] Group 4 - BeiGene's Brukinsa is the most widely approved BTK inhibitor globally, with approvals in over 75 markets [2] - The company plans to conduct a mid-term analysis of the MANGROVE trial in the first half of 2026, comparing Brukinsa combined with Rituximab against Bendamustine combined with Rituximab for first-line treatment of adult patients with mantle cell lymphoma [2] - The other core product, Tislelizumab (百泽安), achieved global sales of 5.297 billion yuan, reflecting an 18.6% year-on-year growth [2] - Tislelizumab is approved in over 50 markets, and the company expects to submit a new indication application for its combination with Zai Lab's (Zanidatamab) for HER2-positive gastric adenocarcinoma in the first half of 2026 [2]